Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

Canadian Cancer Trials Group PRC.3 (CALGB 90203/PRC.3) -- A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer -- was closed to accrual on October 2, 2015.

This trial has met its accrual goal. Canadian sites contributed 191 of the 783 patients randomized. This is 24% of overall accrual and represents a significant accomplishment for an intergroup trial!!

Canadian Cancer Trials Group PR.15 -- Randomized Phase II Feasibility Trial of Image Guided External Beam Radiotherapy (IGRT) With or Without High Dose Rate (HDR) Brachytherapy Boost in Men with Intermediate-Risk Prostate Cancer -- was closed to accrual on September 30, 2015.

PR.15 is a trial led by Canadian Cancer Trials Group. Its primary outcome is feasibility as defined by the ability to randomize 60 consenting patients to treatment with IGRT with or without HDR brachytherapy boost from 6 to 7 Canadian centres over 18 months (beginning after the activation of first centre on March 31, 2014).

Treatment and patient follow-up continues.

Canadian Cancer Trials Group IND.209 -- A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer was closed to accrual on September 25, 2015 after reaching its target accrual.

Although accrual is now closed, treatment and follow up of patients must continue as per protocol until the final analysis is completed.

Thank you to all participating centres, staff and patients for contributing to these studies.